DailyIQ
|
Last updatedUpdating…

AXSM·Axsome Therapeutics Inc.

$174.30
-2.78 (-1.57%)
After Hours
High
$177.00
Open
$176.52
Market Cap
9.33B
52W High
$261.90
Low
$169.30
P. Close
$174.30
P/E
-
52W Low
$117.00
Fwd P/E
35.18
DailyIQ Est.
$300.64
Inst. Ownership
1.0%
Short Interest
5.86%
Days to Cover
5.2
Technical Score (1D)
14
BEARISH
News Sentiment
58
BULLISH
On Oct 5, Baird Equity Asset Management released its Q2 2026 investor letter, noting a sharp rebound in the broader equity market driven by AI investment and resilient earnings. The letter highlighted that the firm’s growth strategy returned 17.7 % net of fees, a figure that fell short of the Russell 2500 Growth Index. Baird identified artificial intelligence as a long‑term value driver and expressed optimism for Axsome Therapeutics’ growth potential within the healthcare sector. The letter also pointed out that the healthcare sector had underperformed during the quarter, yet Baird still saw AXSM as a promising opportunity. This endorsement from a major asset manager underscored the company’s potential appeal to investors seeking growth in a sector that had lagged behind the broader market.
LOW TARGET
$246 +41.1%
2 analysts
MEAN TARGET
$285 +63.3%
5 analysts
HIGH TARGET
$380 +118.0%
23 analysts
PRICE RANGE
$246.00 - $380.00
SB / B / H / S / SS
10/16/2/1/1
DAILYIQ EST.
$300.64 (+72.4%)
Bought (1Y)
0 shares
$0
Sold (1Y)
211,352 shares
$48.9M
Jacobson Mark L.Chief Operating Officer
Option Exercise10,000 shares2026-09-03
Jacobson Mark L.Chief Operating Officer
Sell10,000 shares2026-09-03
Jacobson Mark L.Chief Operating Officer
Option Exercise10,000 shares2026-09-03
TABUTEAU HERRIOTChief Executive Officer
Option Exercise4,660 shares2026-08-06
TABUTEAU HERRIOTChief Executive Officer
Sell4,660 shares2026-08-06
View full insider trading history →
42/ 100
Bearish
Overall: Bearish
✓Revenue growing year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-28.7%
Revenue CAGR
133.7%
Current Ratio
1.55x
Debt / Equity
2.13x
Return on Equity
-207.5%
View full financials →

EPS

EstBeatMiss
$-1.18$-0.98$-0.79$-0.59$-0.39Q2'25Q3'26
QtrEstActual+/−
Q3'26$-0.49 - -
Q2'25$-1.09$-0.97+10.7%

Revenue

EstBeatMiss
$262M$262M$262M$262M$262MQ3'26
QtrEstActual+/−
Q3'26$262M - -
Q2'25 - - -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

AXSM Stock Snapshot

BEARISH14/100
$174.34+$0.04 (0.0%)
Market cap
9.33B
Day range
$169.30 – $177.00
News sentiment
58/100 · Neutral
Analyst target
$284.63 (+63.3%)
Consensus
Buy · 30 analysts
52-week range+49.0% off low · -33.4% from high
$117.00$261.90
Price $174.34 DailyIQ Est. $300.64

Price action on AXSM is defensive - rallies are being sold rather than extended. At this size, a single catalyst moves the stock further than it would a larger peer.

Sector Rotation

Is money rotating into or out of AXSM's sector?

Axsome Therapeutics Inc. sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, AXSM ranks 10th of 15 tracked industries, lagging.

Sector rank
#8 of 12
Sector state
Lagging
Sector rotation score
0
Industry rank
#10 of 15

Options Market

What is the options market pricing for AXSM?

CallsPuts

For Axsome Therapeutics Inc.'s nearest expiry (2026-10-16, 10 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 2.44), with at-the-money implied volatility around 59.9%. The options market is pricing roughly a ±9.9% move by that expiry — a range of about $167.77–$204.51.

Put/call ratio (2026-10-16)
2.44
ATM implied volatility
59.9%
Total open interest
3,313
Expected move by 2026-10-16
±9.9% ($167.77–$204.51)

Analyst Rating Changes

Are analysts turning bullish or bearish on AXSM?

Deutsche Bank most recently reiterated its rating on Axsome Therapeutics Inc. to Buy on Sep 29, 2026 with a price target of $267 (from $280). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Deutsche Bank — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 29, 2026Deutsche BankMaintainedBuy$280 → $267
Sep 25, 2026Morgan StanleyMaintainedEqual-Weight$251 → $247
Sep 23, 2026Truist SecuritiesMaintainedBuy$200 → $285
Sep 18, 2026Piper SandlerReiteratedOverweight$258
Aug 31, 2026HC Wainwright & Co.ReiteratedBuy$290
Aug 12, 2026MizuhoMaintainedOutperform$306 → $316
Aug 11, 2026Morgan StanleyMaintainedEqual-Weight$242 → $251
Aug 11, 2026RBC CapitalMaintainedOutperform$304 → $297
Aug 11, 2026GuggenheimMaintainedBuy$260 → $275
Aug 11, 2026Wells FargoMaintainedOverweight$255 → $256
Aug 11, 2026NeedhamMaintainedBuy$267 → $268
Jul 31, 2026MizuhoMaintainedOutperform$310 → $306

Held by These ETFs

AXSM is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.

News Sentiment Analysis

Sentiment gathered from recent headlines

58/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Baird Equity Asset Management released its Q2 2026 investor letter, noting a sharp rebound in the broader equity market driven by AI investment and resilient earnings. The letter highlighted that while the overall growth strategy underperformed the Russell 2500 Growth Index, it still delivered 17.7% net of fees. Baird identified AI as a long‑term value driver and expressed optimism for AXSM’s growth potential within the healthcare sector, despite the sector’s relative underperformance during the quarter.
What did this article say?
Axsome Therapeutics reported a 65.5% revenue increase to $638.5 million in FY2025, driven by its approved CNS products Auvelity and Sunosi. The company settled Sunosi patent litigation, establishing a framework for generic entry in 2040, which provides long‑term clarity for that product line. Compared to Vertex Pharmaceuticals, Axsome presents a higher growth trajectory but lower cash‑flow maturity, making it an attractive high‑risk, high‑reward biotech option for investors seeking expansion in central nervous system disorders.
What did this article say?
Deutsche Bank analyst David Hoang kept a buy rating on Axsome Therapeutics (NASDAQ:AXSM) but reduced the price target from $280 to $267. The adjustment reflects a reassessment of the company’s valuation. The rating remains positive, though the lower target signals a modest headwind for the stock.
What did this article say?
Morgan Stanley analyst Sean Laaman reduced Axsome Therapeutics’ price target from $251 to $247 while keeping the stock on an equal‑weight recommendation. The downgrade reflects concerns over the company’s valuation relative to peers and the lack of recent upside catalysts. The firm’s assessment suggests that the current market price may be slightly overvalued, but no immediate negative catalysts were identified.
What did this article say?
Axsome Therapeutics (NASDAQ:AXSM) delivered an annualized return of 37.87% over the past decade, outperforming the broader market by 24.39%. The company’s share price has risen steadily, reflecting investor confidence in its pipeline and management. No new product approvals or regulatory changes were reported in the article, so the performance is presented as historical context rather than a catalyst for future moves.
What did this article say?
Truist Securities analyst Srikripa Devarakonda maintained a Buy rating on Axsome Therapeutics and increased the price target from $200 to $285. The upgrade reflects confidence in the company’s pipeline and recent clinical progress. The higher target suggests a positive outlook for the stock’s valuation moving forward.
What did this article say?
Truist has increased its price target for Axsome Therapeutics (AXSM) to $285 from $200, reflecting a bullish view on the company’s growth prospects. The upgrade comes alongside a continued buy recommendation, underscoring confidence in AXSM’s pipeline and market positioning. This material upside signals a potential rally in the stock as investors reassess the company’s valuation.
What did this article say?
Axsome Therapeutics released results from the Shared Goals: Navigating Alzheimer’s Agitation survey, highlighting that 97% of caregivers noted a negative impact on quality of life and 75% wished symptoms had been recognized earlier. The survey, conducted by The Harris Poll and presented at Psych Congress 2026, underscores the unmet need for early detection and intervention in agitation. While the findings reinforce the importance of Axsome’s therapeutic pipeline, they do not directly alter current guidance or market expectations.
What did this article say?
Axsome Therapeutics reports a noticeable uptick in AUVELITY prescriptions following its recent Alzheimer’s launch, indicating stronger market uptake than initially projected. The accelerated prescription trend suggests early adoption by clinicians and a potential boost to the company’s revenue trajectory.

Technical Analysis

Real-time indicators across multiple timeframes

14
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
1 tracked managers · $126.10M combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Citadel Advisors LLC• Hold515,1780.96%$126.10M2026-09-02
Q2 2026 flow:515.2K sh bought ($126.10M)0 sh sold ($0)net +515.2K sh (+$126.10M)
View full institutional holdings history →

Discover More

TBXU
Direxion Daily Biotech Top 5 Bull 2X ETF
$36.64
+0.00%
WAT
Waters Corporation
$436.43
-0.01%
COO
The Cooper Companies, Inc.
$56.43
+0.02%
STE
STERIS plc
$208.65
+0.03%
ELIL
Direxion Daily LLY Bull 2X Shares
$27.56
+0.00%
REGN
Regeneron Pharmaceuticals, Inc.
$738.72
+0.00%
BIIB
Biogen Inc.
$222.51
-0.23%
DHR
Danaher Corporation
$215.61
+0.00%
RMD
ResMed Inc.
$220.69
+0.00%
HALO
Halozyme Therapeutics Inc.
$110.00
+0.26%